Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2020

Hofman Véronique, Benzaquen Jonathan, Heeke Simon, Lassalle Sandra, Poudenx Michel, Long Elodie, Lantéri Elisabeth, Bordone Olivier, Lespinet Virginie, Tanga Virginie, Bonnetaud Christelle, Bille Yvonne, Ilié Marius, Marquette Charles, Barlesi Fabrice, Boutros Jacques, Hofman Paul

Abstract excerpt

INTRODUCTION: International guidelines recommend BRAF mutational status assessment in treatment-naive advanced non-squamous non-small cell lung carcinoma (NSCLC) patients since the presence of a BRAFV600 mutation enables specific BRAF inhibitor treatment. For this purpose, the mutational status needs to be obtained in 10 working days. Herein, we prospectively evaluated the feasibility of systematic assessment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to France

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Laboratories

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 32408133
DOI: 10.1016/j.lungcan.2020.04.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).PMID 32408133Read ↗

Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.Semantic proximity Read ↗

Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study.Semantic proximity Read ↗

Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.Semantic proximity Read ↗

Selection Strategies and Practical Application of BRAF V600E-Mutated Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

Treatment outcome of NSCLC patients with BRAF mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanySemantic proximity Read ↗

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.Semantic proximity Read ↗

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?Semantic proximity Read ↗

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.Semantic proximity Read ↗

A BRAF new world.Semantic proximity Read ↗

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.Semantic proximity Read ↗

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Semantic proximity Read ↗

Advanced Non-small Cell Lung Cancer: EGFR Mutation Analysis Using Pyrosequencing and the Fully Automated qPCR-Based IdyllaTM System.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.